Monday - Friday, 6:00 - 7:00 PM ET
In this article
In a Monday interview with CNBC’s Jim Cramer, Novo Nordisk
CEO Mike Doustdar suggested the new pill format of the pharmaceutical giant’s weight loss drug will allow more people to use the medicine which had previously been available only as an injectable.
“We are seeing, actually, that the pill is able to expand the market for a large group of people that have been waiting,” Doustdar said. “Predominantly, I would say the major barrier has been the taboo.”
